China drug stock surges after doctor endorses its treatment for Covid
Guangzhou
A MAKER of traditional Chinese medicine products saw its stock surge the most in two years on Friday after one of the nation's top medical advisers reportedly said one of its treatments could potentially inhibit Covid-19.
Speculative traders pushed Guangzhou Baiyunshan Pharmaceutical Holdings up 13 per cent in Hong Kong and by its 10 per cent limit in Shanghai. Guangzhou-based Nanfang Daily cited Zhong Nanshan as saying Baiyunshan's "banlangen" product was effective in a series of in-vitro studies. Mr Zhong is a senior medical adviser to Beijing …
GET BT IN YOUR INBOX DAILY
Start and end each day with the latest news stories and analyses delivered straight to your inbox.
KEYWORDS IN THIS ARTICLE
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Companies & Markets
Volkswagen workers vote decisively to unionise in Tennessee
Sony deal for Paramount would draw added regulatory scrutiny
Bitcoin 'halving' has taken place: CoinGecko
Lululemon to shutter Washington distribution center, lay off 128 employees
Wall Street bonus rules return to regulatory agenda in third try
Honda to invest US$808 million in Brazil by 2030